News | Stent Grafts | August 19, 2016

Endologix Announces First Patients Treated with Ovation Alto Abdominal Stent Graft System

Stent graft designed to expand EVAR to include treatment of patients with complex abdominal aortic aneurysms

August 19, 2016 — Endologix Inc. announced the first two patients with abdominal aortic aneurysms (AAA) have been treated with the Ovation Alto Abdominal Stent Graft System. The patients were treated by Andrew Holden, M.D., and Andrew Hill, M.D., of Auckland City Hospital, Auckland, New Zealand.

Holden commented, “The repositioned sealing ring in the Ovation Alto system expands the EVAR [endovascular aortic repair] treatment of AAA patients to include short and challenging aortic necks, which represents a significant segment of the underserved complex AAA market. We are pleased to be the first center in the world to implant Ovation Alto and look forward to treating more patients and sharing our experience with the clinical community.”

Hill said, “The Ovation Alto system has the potential to increase the number of AAA patients treated with EVAR due to its unique sealing technology and ultra-low profile design. The new system is designed to provide the broadest indications of all infrarenal EVAR devices, which represents an important advancement for physicians and their AAA patients.”

Ovation Alto is the newest device in the Ovation platform of abdominal stent graft systems, which has excellent clinical results reported from the Ovation global pivotal trial and a 501-patient European Post-Market Registry. Ovation Alto expands EVAR to include the treatment of patients with complex AAAs, specifically patients with very short or otherwise challenging aortic neck anatomy. This is achieved by the conformable O-rings with CustomSeal polymer that have been repositioned near the top of the endograft, providing seal just below the renal arteries. The Ovation platform is the lowest profile U.S. Food and Drug Administration (FDA)-approved EVAR device and has been used successfully in the treatment of approximately 10,000 patients worldwide.

Ovation Alto is an investigational device and currently not approved in any market.  It is expected to be introduced into Europe in 2017 and the United States in 2018.

For more information: www.endologix.com 


Related Content

News | Stent Grafts

April 26, 2023 — Medtronic today announced its Endurant abdominal aortic aneurysm (AAA) stent graft system continues to ...

Home April 26, 2023
Home
News | Stent Grafts

January 12, 2023 — Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized ...

Home January 12, 2023
Home
News | Stent Grafts
May 4, 2022 – Seeking to bolster its development of a biocompatible graft that promises to reshape the future of cardiac ...
Home May 04, 2022
Home
News | Stent Grafts

October 9, 2019 — Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug ...

Home October 09, 2019
Home
News | Stent Grafts

October 8, 2019 — PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) ...

Home October 08, 2019
Home
News | Stent Grafts

July 10, 2019 — W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable ...

Home July 10, 2019
Home
Technology | Stent Grafts

May 15, 2019 — W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted ...

Home May 15, 2019
Home
News | Stent Grafts

February 14, 2019 — Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft ...

Home February 14, 2019
Home
Technology | Stent Grafts

February 7, 2019 — Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant ...

Home February 07, 2019
Home
News | Stent Grafts

January 7, 2019 — Endologix Inc. announced that in order to ensure optimal outcomes for patients, unrestricted sales and ...

Home January 07, 2019
Home
Subscribe Now